Prostate Adenocarcinoma Recurrence in the Vas Deferens Unveiled by 99m Tc-PSMA SPECT/CT Imaging.
We present a case involving a 77-year-old man with prostate cancer who underwent radical prostatectomy with negative surgical margins.
APA
Raeisi N, Saber Tanha A, et al. (2025). Prostate Adenocarcinoma Recurrence in the Vas Deferens Unveiled by 99m Tc-PSMA SPECT/CT Imaging.. Clinical nuclear medicine, 50(12), e700-e701. https://doi.org/10.1097/RLU.0000000000005881
MLA
Raeisi N, et al.. "Prostate Adenocarcinoma Recurrence in the Vas Deferens Unveiled by 99m Tc-PSMA SPECT/CT Imaging.." Clinical nuclear medicine, vol. 50, no. 12, 2025, pp. e700-e701.
PMID
40357624
Abstract
We present a case involving a 77-year-old man with prostate cancer who underwent radical prostatectomy with negative surgical margins. After 10 years without follow-up, his serum prostate-specific antigen level increased to 2.76 ng/mL, suggesting disease recurrence. Due to limited access to 68 Ga-PSMA PET/CT, a 99m Tc-HYNIC-PSMA SPECT/CT was conducted, which identified PSMA uptake in the bilateral vas deferens, a rare site for recurrence. While recurrence in the vas deferens has been previously reported using 68 Ga-PSMA PET/CT or PET/MR, this novel experience with 99m Tc-PSMA SPECT/CT highlights its potential utility in detecting such recurrences. This is particularly relevant in low-income countries where access to PET/CT may be limited.
MeSH Terms
Humans; Male; Prostatic Neoplasms; Aged; Adenocarcinoma; Single Photon Emission Computed Tomography Computed Tomography; Vas Deferens; Recurrence; Positron Emission Tomography Computed Tomography; Neoplasm Recurrence, Local; Organotechnetium Compounds
같은 제1저자의 인용 많은 논문 (4)
- Superior Diagnostic Performance of 99mTc-FAPI-46 SPECT/CT Versus 18FDG PET/CT in Detecting Peritoneal Involvement in Mucinous Adenocarcinoma of the Colon.
- 99m Tc-FAPI-46 Uptake in Medication-Related Jaw Osteonecrosis.
- 177Lu-FAPI-2286 Therapy in Metastatic Breast Cancer: A Case Study Highlighting the Potential Risk of Tumor Dedifferentiation and Hormonal Marker Elevation.
- 177Lu-FAPI-2286 Therapy in a Patient With Radio-iodine Refractory Papillary Thyroid Carcinoma: A Favorable Clinical and Biochemical Response.